cardiovascular

Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Insurer's foundation heart initiative addresses cardiovascular disparitiesThe Independence Blue Cross Foundation Healthy Hearts Initiative aims to improve survival rates for sudden cardiac arrest, increase CPR preparedness.
Cardiovascular drugs: Current spending, future outlookCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.
Top 3 cardiovascular patient compliance challenges
Top 3 cardiovascular patient compliance challengesStaying compliant with a prescribed treatment regimen gives cardiovascular disease patients the best chance of improving their heart health and reducing future incidences of cardiac events. Here’s how to get patients on board.
Driving down heart disease costs: Tips for plans, providers
Driving down heart disease costs: Tips for plans, providersHeart disease takes a heavy toll on the healthcare system, but promising new treatments are emerging
Telemonitoring of heart failure patients reduces readmissionsStudy demonstrates how new technology can drive higher value healthcare for heart failure patients.
Heart drug improves life expectancyThere is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.
Takeda announces post hoc analysis of data from EXAMINE cardiovascular safety outcomes trialIn patients with type 2 diabetes and recent acute coronary syndrome (ACS), dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin compared to placebo did not increase the risk of heart failure (HF) outcomes, according to data published in The Lancet.